Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

NCT06508775 · tracked via the Priya Life Science Germany tracker

Sponsor

Miltenyi Biomedicine GmbH

Phase

Not applicable

Started

2024-05-05

Last updated

2025-11-26

Condition(s) studied

Melanoma Stage IIIB-cell Non Hodgkin LymphomaPediatric ALLChildhood Non-Hodgkin LymphomaAcute Lymphatic LeukemiaChronic Lymphatic LeukemiaMelanoma Stage IV

Investigational drug(s) / intervention(s)

MB-CART19.1 →MB-CART20.1MB-CART2019.1 →

MB-CART19.1: Assessment of long-term safety and efficacy of MB-CART19.1 treatment.

MB-CART20.1: Assessment of long-term safety and efficacy of MB-CART20.1 treatment.

MB-CART2019.1: Assessment of long-term safety and efficacy of MB-CART2019.1 treatment.

Study summary

The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up. * Patient has provided informed consent prior to enrollment. Exclusion Criteria: * No exclusion criteria

Primary outcome measure(s)

Adverse Events — through study completion, up to 14 years
Percentage of patients with late-onset adverse reactions (AR), serious adverse events (SAE), serious adverse reactions (SAR) and adverse events of special interest (AESI) including relapse or progression of the underlying disease, life-threatening infections, death due to any cause, new and secondary malignancies

Trial sites (7)

Facility	City	Region	Status
Charité Universitätsmedizin Berlin	Berlin	Germany	Recruiting
Universitätsklinikum Köln	Cologne	Germany	Active Not Recruiting
Uniklinikum Erlangen	Erlangen	Germany	Active Not Recruiting
Universitätsmedizin Göttingen	Göttingen	Germany	Active Not Recruiting
Universitätsklinikum Münster	Münster	Germany	Recruiting
Universitätsklinikum Tübingen	Tübingen	Germany	Active Not Recruiting
Universitäts-Kinderklinik Würzburg	Würzburg	Germany	Active Not Recruiting

More Miltenyi Biomedicine GmbH trials in Germany

CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease Recruiting

MB-CART2019.1 in Refractory Multiple Sclerosis Recruiting

Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms Recruiting

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) Active, not recruiting

MB-CART19.1 in Refractory SLE Recruiting

Other trials for the same condition

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients Recruiting

More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL) Recruiting

Digital Health Promotion for Children With Congenital Heart Disease and Their Guardians Recruiting

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06508775 on ClinicalTrials.gov ↗ ← All trials in Germany